sitaxsentan (Thelin) + sitaxsentan (Thelin) + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cardiac Surgery Subjects
Conditions
Cardiac Surgery Subjects, Subjects Undergoing CABG and/or Cardiac Valve Replacement
Trial Timeline
Aug 10, 2006 → Mar 31, 2008
NCT ID
NCT00838383About sitaxsentan (Thelin) + sitaxsentan (Thelin) + Placebo
sitaxsentan (Thelin) + sitaxsentan (Thelin) + Placebo is a phase 2 stage product being developed by Pfizer for Cardiac Surgery Subjects. The current trial status is completed. This product is registered under clinical trial identifier NCT00838383. Target conditions include Cardiac Surgery Subjects, Subjects Undergoing CABG and/or Cardiac Valve Replacement.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00838383 | Phase 2 | Completed |
Competing Products
20 competing products in Cardiac Surgery Subjects